Vancomycin Hydrochloride Oral Solution and its Scale-up Production Method
By using citric acid and sodium dihydrogen phosphate to build a buffer system in the preparation of vancomycin hydrochloride oral solution, combined with β-cyclodextrin and amino acid masking, and with the addition of defoaming agents and vacuum negative pressure defoaming, the stability and impurity problems of vancomycin hydrochloride oral solution in the scale-up production of existing technologies have been solved, and the production of high-quality, uniform oral solution with good masking has been achieved.
Patent Information
- Application Number
- CN202611188017.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-06
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2046-08-06
AI Technical Summary
Existing vancomycin hydrochloride oral solutions suffer from problems such as poor stability, increased impurities, excessive foaming, and cumbersome operation during scale-up production, making it difficult to meet the requirements of large-scale industrial production.
Citric acid and/or sodium dihydrogen phosphate were used as pH adjusters to build a buffer system. Combined with excipients such as disodium ethylenediaminetetraacetate, potassium sorbate, β-cyclodextrin and amino acids, a blank matrix was formed. Vancomycin hydrochloride was added and the volume was adjusted. Polydimethylsiloxane and vacuum negative pressure were used for defoaming to achieve a double reduction in the hydrolysis of active ingredients and the generation of impurities. The stability of the drug solution was ensured by two-stage filtration.
It achieves high-quality standards for vancomycin hydrochloride oral solution, with good stability and excellent taste masking effect, making it suitable for large-scale industrial production. The solution is uniform and has a significant defoaming effect, reducing the risk of drug degradation.
Smart Images

Figure CN122681796B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, specifically relating to a vancomycin hydrochloride oral solution and its scale-up production method. Background Technology
[0002] Vancomycin hydrochloride is a glycopeptide antibacterial drug. Its oral solution is marketed under the brand name FIRVANQ KIT, and its molecular formula is C2. 66 H 75 Cl2N9O 24 •HCl, molecular weight: 1485.71, its structural formula is as follows: ; Vancomycin hydrochloride is a narrow-spectrum glycopeptide antibiotic derived from the fermentation of *Nocardia orientalis* (formerly known as *Nocardia orientalis*). Approved by the FDA in 1958, it exerts its potent bactericidal effect by inhibiting cell wall synthesis in Gram-positive bacteria. At the mechanism of action, vancomycin hydrochloride exhibits strong bactericidal activity against most Gram-positive anaerobic bacteria, including *Clostridium difficile*. The drug specifically binds to the terminal D-alanyl-D-alanine residues of bacterial cell wall peptidoglycan precursors, simultaneously blocking transglycosylase and transpeptidase catalytic reactions, inhibiting the elongation and cross-linking of cell wall peptidoglycan chains, leading to bacterial lysis and death due to intracellular osmotic pressure imbalance. At high concentrations, it can also disrupt bacterial cell membrane permeability and inhibit bacterial RNA replication, remaining highly sensitive to metronidazole-resistant and β-lactam-resistant strains.
[0003] Injectable vancomycin cannot act on the intestines; only oral administration can specifically treat Clostridium difficile and Staphylococcus aureus in the intestines. Vancomycin has difficulty penetrating intact intestinal epithelial mucosa, and after oral administration, it is almost not absorbed by the intestines. The vast majority of the drug remains in the colon and rectum, creating a drug environment far exceeding the minimum inhibitory concentration (MIC) to directly kill Clostridium difficile colonizing the intestines. This significantly avoids the nephrotoxicity and ototoxicity associated with intravenous administration. Simultaneously, it reduces the sustained release of Clostridium difficile toxins, alleviating intestinal mucosal inflammation and watery diarrhea symptoms, making it a core first-line drug for the clinical treatment of Clostridium difficile-associated diarrhea (CDAD). For severely ill patients with mucosal erosion and ulceration, the damaged intestinal wall may absorb a small amount of vancomycin, posing a slight risk of systemic exposure. Conventional formulations lack specific mucosal protection designs, resulting in shortcomings in drug safety.
[0004] Currently, clinical oral medications include dry suspensions and capsules. Dry suspensions require immediate reconstitution, which is cumbersome and unsuitable for nasogastric feeding and critically ill patients. Their formulations contain sucralose, an artificial sweetener, which is detrimental to patients with diabetes and insulin resistance. Furthermore, the use of sodium benzoate as a preservative can cause significant irritation to the intestinal mucosa. Capsules have a bitter taste, poor compliance, lack a stable buffering system after water dissolution, and have insufficient physicochemical stability. Clinically, injectable powders are sometimes temporarily diluted with water for oral administration, but this results in easy degradation of the solution, severe colloidal aggregation, excessive foaming, inaccurate dosage, and inability to store the medication; it is only suitable for emergency use. Existing oral products generally lack effective synergistic excipient systems for taste masking, colloidal dispersion, and intestinal protection, exhibiting significant shortcomings in both clinical applicability and safety.
[0005] Vancomycin hydrochloride aqueous solutions readily form colloidal aggregates, generating a large amount of fine foam during solution preparation. This poses significant challenges for large-scale production and easily leads to quality issues such as filter cartridge blockage, filtration flux reduction, and excessive fill volume variation. Conventional processes often adjust the pH value after the drug is completely dissolved. However, vancomycin hydrochloride readily forms localized extreme pH microenvironments when exposed to acids or alkalis, accelerating drug hydrolysis, increasing impurities, and resulting in poor process stability. Furthermore, filtration often employs single-stage methods, which cannot effectively retain colloidal aggregates, leading to membrane clogging and poor batch stability. Overall, existing production processes suffer from low defoaming efficiency, high drug degradation risk, and insufficient filtration stability, making it difficult to meet the requirements of large-scale, highly homogeneous, and low-impurity GMP production. Summary of the Invention
[0006] The purpose of this invention is to address the problems of existing vancomycin hydrochloride oral solutions, such as the use of sucrose and flavoring to mask the taste, which is not conducive to long-term use by diabetic patients, the instability of vancomycin hydrochloride aqueous solution, which is prone to degradation, increased impurities and discoloration, the cumbersome preparation of dry suspension, excessive foaming during production, and the tendency of active ingredients to be easily hydrolyzed when adjusting pH value at the endpoint. This invention aims to provide a vancomycin hydrochloride oral solution that can be easily used in scaled-up industrial production and can be quickly prepared with good taste masking effect, fewer impurities, stable and uniform solution, and high quality standards.
[0007] The second objective of this invention is to provide a scale-up production method for the above-mentioned vancomycin hydrochloride oral solution. In the preparation of the oral solution, citric acid and / or sodium dihydrogen phosphate are used as pH adjusters to build a buffer system. This system controls the pH of the blank matrix, composed of disodium ethylenediaminetetraacetate, potassium sorbate, β-cyclodextrin (e.g., hydroxypropyl-β-cyclodextrin), amino acids (e.g., L-glutamine), and polydimethylsiloxane, to 2.8-3.2. After adding the active ingredient vancomycin hydrochloride and adjusting the volume, the solution is combined with the chelating agent disodium ethylenediaminetetraacetate to achieve a double reduction in the possibility of vancomycin hydrolysis, significantly reducing impurity formation. Through the dual action of the defoamer (polydimethylsiloxane) and vacuum negative pressure, a good defoaming effect is achieved. The entire preparation method is simple, the conditions are mild, the taste masking effect is good, impurities are few, and the solution is stable and uniform, making it suitable for large-scale industrial production.
[0008] The technical solution of the present invention is as follows: This invention provides a vancomycin hydrochloride oral solution, each 1 mL of which contains the following components by weight: 14-55 mg of active ingredient (based on vancomycin), 0.005-0.060 mg of disodium ethylenediaminetetraacetate, 0.08-1.66 mg of potassium sorbate, and 0.004-0.084 mg of polydimethylsiloxane; the active ingredient is added in the form of vancomycin hydrochloride, and β-cyclodextrin and amino acids are also added; during the preparation of the oral solution, a pH adjuster is used to adjust it to 2.5-3.5.
[0009] In this invention, the β-cyclodextrin can be hydroxypropyl-β-cyclodextrin, methyl-β-cyclodextrin, or sulfobutyl-β-cyclodextrin, preferably hydroxypropyl-β-cyclodextrin. The amino acid can be L-glutamine or L-glycine, preferably L-glutamine. The molar ratio of β-cyclodextrin to vancomycin hydrochloride is 1.2~1.8:1, the molar ratio of vancomycin hydrochloride to amino acid is 1:2.5~4.0, and the molar ratio of β-cyclodextrin, vancomycin hydrochloride, and amino acid is 1.2~1.8:1:2.5~4.0, preferably 1.4:1:3.2.
[0010] The pH adjuster is citric acid and / or sodium dihydrogen phosphate. For this invention, anhydrous or hydrated sodium dihydrogen phosphate can be used, such as sodium dihydrogen phosphate monohydrate and sodium dihydrogen phosphate dihydrate. Citric acid and sodium dihydrogen phosphate synergistically construct a buffer system, which is more stable and exhibits less fluctuation compared to adjusting the pH value with a single component.
[0011] Raw materials, water for injection, and production pipelines may introduce trace amounts of iron and copper ions. These heavy metals can catalyze the oxidation of vancomycin and the hydrolysis of glycosidic bonds, leading to an increase in impurities and a yellowing of the drug solution. Using disodium ethylenediaminetetraacetic acid (EDTA) as a chelating agent, disodium EDTA can complex free heavy metals in the drug solution (these heavy metals catalyze the oxidation of vancomycin and the hydrolysis of glycosidic bonds, reducing impurity formation), eliminating the catalytic degradation pathway, and significantly extending the shelf life of the finished product. Furthermore, this product cannot be sterilized by moist heat; only filtration sterilization is possible. Potassium sorbate, under acidic conditions, acts as an antibacterial and preservative agent. During the storage and use of the drug solution, potassium sorbate inhibits microbial growth, ensuring medication safety.
[0012] This invention creatively employs β-cyclodextrin encapsulation technology. β-cyclodextrin, a hollow, barrel-shaped molecule, swells upon absorbing water, exhibiting a flexible structure. Vancomycin hydrochloride, with its numerous hydrophobic aromatic rings and phenolic hydroxyl groups, forms the core structure triggering bitterness in the mouth. It can embed itself into the hydrophobic cavity of the cyclodextrin, forming an inclusion complex. The bitter groups are encapsulated within this cavity, preventing them from contacting the bitter taste receptor proteins on the taste buds of the tongue, thus blocking the generation of bitterness signals at the source. Simultaneously, cyclodextrin disrupts the intermolecular hydrogen bonds of vancomycin, reducing colloidal aggregation, decreasing the viscosity of the drug solution, and facilitating subsequent filtration. However, its effect on encapsulating the astringent and metallic taste caused by exposed polar hydroxyl and amino groups of the drug is limited. The addition of amino acids precisely solves this problem. Amino acids, containing amino and carboxyl groups, can form intermolecular hydrogen bonds with the exposed polar groups of vancomycin, binding these sites that easily trigger astringent and metallic tastes, reducing the probability of these groups contacting the taste buds. β-Cyclodextrin and amino acids work synergistically to achieve a good taste masking effect. After oral administration, the cyclodextrin inclusion complex slowly releases the drug, avoiding local irritation of the intestinal mucosa by a high instantaneous drug concentration. The amino acids can provide nutrition to the intestinal epithelial cells, repair the damaged mucosa, and reduce intestinal discomfort.
[0013] In a preferred embodiment, the vancomycin hydrochloride oral solution provided by the present invention comprises the following components by weight per 1 mL: 0.008-0.045 mg of disodium ethylenediaminetetraacetate, 0.28-1.26 mg of potassium sorbate, and 0.014-0.064 mg of polydimethylsiloxane.
[0014] In a more preferred embodiment, the vancomycin hydrochloride oral solution provided by the present invention comprises the following components by weight per 1 mL: 0.012-0.030 mg of disodium ethylenediaminetetraacetate, 0.48-0.96 mg of potassium sorbate, and 0.024-0.054 mg of polydimethylsiloxane.
[0015] For example, the vancomycin hydrochloride oral solution provided by the present invention contains the following components by weight per 1 mL: 0.021 mg disodium ethylenediaminetetraacetate, 0.72 mg potassium sorbate, 24.9 mg hydroxypropyl-β-cyclodextrin, 4.43 mg L-glutamine, and 0.039 mg polydimethylsiloxane.
[0016] For example, the vancomycin hydrochloride oral solution provided by the present invention contains the following components by weight per 1 mL: 0.012 mg disodium ethylenediaminetetraacetate, 0.48 mg potassium sorbate, 23.68 mg methyl-β-cyclodextrin, 3.69 mg L-glutamine, and 0.024 mg polydimethylsiloxane.
[0017] For example, the vancomycin hydrochloride oral solution provided by the present invention contains the following components by weight per 1 mL: 0.030 mg disodium ethylenediaminetetraacetate, 0.96 mg potassium sorbate, 27.16 mg sulfobutyl-β-cyclodextrin, 3.03 mg L-glycine, and 0.054 mg polydimethylsiloxane.
[0018] This invention also provides a method for scale-up production of the above-mentioned vancomycin hydrochloride oral solution, comprising the following steps: (1) Add citric acid, sodium dihydrogen phosphate, disodium ethylenediaminetetraacetate and potassium sorbate to a portion of water for injection and stir until completely dissolved; (2) Add β-cyclodextrin to the mixed solution obtained in step (1), stir continuously until it is completely swollen and clear, then add amino acids, stir to dissolve, then add polydimethylsiloxane and stir to disperse evenly, adjust its pH to 2.8-3.2 with a pH adjuster to prepare a blank matrix solution; (3) Under light-protected conditions, add vancomycin hydrochloride to a portion of water for injection and stir until completely dissolved. The resulting solution is then mixed with the blank matrix solution in step (2), stirred and dispersed evenly. The remaining water for injection is added to make up to volume, and the solution is stirred evenly to obtain the drug solution. The pH of the solution is measured to be 2.5-3.5. (4) After the medicine solution is prepared, it is vacuum defoamed, sterilized and filtered, and then filled to obtain the oral solution.
[0019] For the purposes of this invention, in step (1), the amount of water for injection added is 55-70% of its total amount.
[0020] In step (2), β-cyclodextrin needs to be hydrated and swollen in a buffer solution to ensure that the inclusion cavity is fully expanded; then amino acids are added to dissolve it to avoid electrolyte interference with cyclodextrin hydration; polydimethylsiloxane is added after the aforementioned excipients are completely dissolved to prevent hydrophobic silicone oil from coating the cyclodextrin powder and hindering dissolution (adding silicone oil in advance will adhere to the surface of the cyclodextrin dry powder, preventing water molecules from penetrating into the powder and greatly prolonging the swelling time). It is added before the active ingredient vancomycin hydrochloride is added to precisely control the foam generation during the dissolution stage of the active pharmaceutical ingredient, taking into account both the clarity of the drug solution and the defoaming effect.
[0021] In this invention, in step (2), the pH is adjusted to 2.8-3.2 using a pH adjuster (aqueous citric acid solution and / or aqueous sodium dihydrogen phosphate solution) to prepare a blank matrix solution. For example, the concentration of the aqueous citric acid solution can be 5-20% (w / v), preferably 8-15% (w / v); the concentration of the aqueous sodium dihydrogen phosphate solution is 4-15% (w / v), preferably 8-10% (w / v).
[0022] In step (2), the pH value is adjusted first and then vancomycin hydrochloride is added to make up the volume to avoid the local pH value of vancomycin hydrochloride being too high or too low, thereby reducing the risk of hydrolysis.
[0023] For the present invention, in step (3), the amount of water for injection added is 15-35% of its total amount, preferably 20-25%. The main component of vancomycin hydrochloride is vancomycin B, which can be in amorphous or crystalline state, and the amount added is calculated according to the efficacy of the raw material. When preparing the vancomycin hydrochloride aqueous solution, it is necessary to avoid light, the container should be shielded from light, and the workshop should be exposed to yellow light; after the vancomycin hydrochloride is completely dissolved in water and stirred evenly, it is added to the above blank matrix. When adding, the blank matrix is in a low-temperature stirring state. After the addition is completed, continue stirring for 10-20 minutes, and add water to make up the volume; take the drug solution to test its pH value to ensure that it is within 2.5-3.5.
[0024] In this invention, during the mixing and stirring process in steps (2) to (4), the β-cyclodextrin and vancomycin colloidal complex easily traps air to form a large number of stable and fine microbubbles, which are difficult to remove quickly and completely by vacuum degassing alone. In this invention, polydimethylsiloxane is first added, which uses its extremely low surface tension to spread on the foam liquid film to generate a tension difference, causing the foam to break down and pre-break most of the visible foam and disassemble the stable microbubble structure; then, it is combined with vacuum negative pressure to remove free microbubbles in the system. The synergistic effect of the two significantly shortens the degassing time, avoids residual bubbles from clogging the subsequent sterilization filter membrane, and eliminates the volume difference caused by bubbles in the filling process, ensuring the clarification of the drug solution and the continuity of the production process.
[0025] In this invention, in step (4), after the defoamer (polydimethylsiloxane) has basically eliminated the large foam, a vacuum negative pressure is used to remove the small bubbles in the liquid. The negative pressure is controlled at -0.090 to -0.095 MPa, preferably -0.092 MPa. After defoaming, the negative pressure is allowed to stand for 3 to 10 minutes until no more bubbles are released.
[0026] In this invention, during sterilization filtration in step (4), a two-stage filtration method of primary filtration and fine filtration is adopted. The pore sizes of the primary filtration and fine filtration are 1.0 μm and 0.22 μm, respectively. The filter membrane material is polypropylene or polyethersulfone. Bubble point integrity test is performed before and after filtration to ensure sterility control.
[0027] The advantages of using the technical solution of this invention are as follows: This invention addresses several issues with existing vancomycin hydrochloride oral solutions. Firstly, the use of sucrose and flavorings to mask the taste makes long-term use unsuitable for diabetic patients. Secondly, the unstable aqueous solution of vancomycin hydrochloride is prone to degradation, increased impurities, and discoloration. Thirdly, the preparation of dry suspensions is cumbersome, resulting in excessive foaming during production. Fourthly, pH adjustments at the endpoint can lead to hydrolysis of the active ingredient. This invention utilizes citric acid and / or sodium dihydrogen phosphate as pH adjusters to construct a buffer system, controlling the pH of the blank matrix (composed of disodium ethylenediaminetetraacetate, potassium sorbate, β-cyclodextrin, amino acids, and polydimethylsiloxane) to 2.8-3.2. Fifthly, this invention innovatively introduces β-cyclodextrin encapsulation technology, embedding numerous hydrophobic aromatic rings and phenolic hydroxyl groups of vancomycin hydrochloride into the hydrophobic cavities of the cyclodextrin to form inclusion complexes. The amino acids, with their amino and carboxyl groups, form intermolecular hydrogen bonds with the exposed polar groups of vancomycin, achieving a dual masking of taste. The pH of the blank matrix is controlled before adding the active ingredient, vancomycin hydrochloride, to adjust the volume. Combined with the chelating agent, disodium EDTA, this dually reduces the possibility of vancomycin hydrolysis, significantly reducing impurity formation. The defoaming effect is further enhanced by the dual action of the defoamer (polydimethylsiloxane) and vacuum negative pressure. These three dual actions work together to allow for easy and rapid preparation of a vancomycin hydrochloride oral solution with good taste masking, few impurities, stable and uniform solution, and high quality standards in large-scale industrial production. The entire preparation method is simple, the conditions are mild, and it is suitable for large-scale industrial production. Attached Figure Description
[0028] Figure 1 Comparison of the taste of the liquid medicines in Examples 1-3 and the reference preparation; Figure 2 Comparison of the taste of the liquid medicine between Comparative Example 1 and the reference preparation. Detailed Implementation
[0029] The present invention can be better understood from the following embodiments. However, those skilled in the art will readily understand that the descriptions in the embodiments are for illustrative purposes only and should not, and will not, limit the invention as detailed in the claims.
[0030] Example 1 A method for large-scale production of vancomycin hydrochloride oral solution includes the following steps: (1) Add 360L of water for injection to a 1000L mixing tank, and add 1.92kg of citric acid, 0.84kg of sodium dihydrogen phosphate, 0.021kg of disodium ethylenediaminetetraacetic acid (EDTA) and 0.72kg of potassium sorbate while stirring, and stir until completely dissolved; (2) Add 24.90 kg of hydroxypropyl-β-cyclodextrin to the mixed solution obtained in step (1), and stir continuously for 0.5 h until it is completely swollen and clear. First add 4.43 kg of L-glutamine, stir to dissolve, then add 0.039 kg of polydimethylsiloxane, stir to disperse evenly, and adjust its pH to 3.05 with citric acid aqueous solution and / or sodium dihydrogen phosphate aqueous solution to prepare a blank matrix solution; (3) Under light-protected conditions, add 180L of water for injection to another mixing tank, add 15.23kg of vancomycin hydrochloride, stir until completely dissolved, then mix with the blank matrix solution in step (2), stir for 15min to mix evenly, add the remaining water for injection to make up to 1000L, stir evenly to obtain the drug solution, and measure its pH to be 3.22. (4) After the drug solution is prepared, vacuum defoaming is performed with a negative pressure of -0.092MPa until there are basically no bubbles rising in the observation microscope. Secondary sterilization filtration is performed using polypropylene filter membranes with pore sizes of 1.0μm and 0.22μm. 150mL / vial is then filled to obtain the oral solution.
[0031] Example 2 A method for large-scale production of vancomycin hydrochloride oral solution includes the following steps: (1) Add 330L of water for injection to a 1000L mixing tank, and add 1.56kg of citric acid, 1.08kg of sodium dihydrogen phosphate, 0.012kg of disodium ethylenediaminetetraacetic acid (EDTA) and 0.48kg of potassium sorbate while stirring, and stir until completely dissolved; (2) Add 23.68 kg of methyl-β-cyclodextrin to the mixed solution obtained in step (1), and stir continuously for 0.5 h until it is completely swollen and clear. First add 3.69 kg of L-glutamine, stir to dissolve, then add 0.024 kg of polydimethylsiloxane, stir to disperse evenly, and adjust its pH to 2.86 with citric acid aqueous solution and / or sodium dihydrogen phosphate aqueous solution to prepare a blank matrix solution; (3) Under light-protected conditions, add 210L of water for injection to another mixing tank, add 15.34kg of vancomycin hydrochloride, stir until completely dissolved, then mix with the blank matrix solution in step (2), stir for 15min to mix evenly, add the remaining water for injection to make up to 1000L, stir evenly to obtain the drug solution, and measure its pH to be 3.04. (4) After the drug solution is prepared, vacuum defoaming is performed with a negative pressure of -0.090MPa until there are basically no bubbles rising in the observation microscope. Secondary sterilization filtration is performed using polyethersulfone filter membranes with pore sizes of 1.0μm and 0.22μm. 150mL / vial is then filled to obtain the oral solution.
[0032] Example 3 A method for large-scale production of vancomycin hydrochloride oral solution includes the following steps: (1) Add 420L of water for injection to a 1000L mixing tank, and add 2.28kg of citric acid, 1.32kg of sodium dihydrogen phosphate, 0.030kg of disodium ethylenediaminetetraacetic acid (EDTA) and 0.96kg of potassium sorbate while stirring, and stir until completely dissolved; (2) Add 27.16 kg of sulfobutyl-β-cyclodextrin to the mixed solution obtained in step (1), and stir continuously for 0.5 h until it is completely swollen and clear. First add 3.03 kg of L-glycine, stir to dissolve, then add 0.054 kg of polydimethylsiloxane, stir to disperse evenly, and adjust its pH to 3.17 with citric acid aqueous solution and / or sodium dihydrogen phosphate aqueous solution to prepare a blank matrix solution; (3) Under light-protected conditions, add 120L of water for injection to another mixing tank, add 15.03kg of vancomycin hydrochloride, stir until completely dissolved, then mix with the blank matrix solution in step (2), stir for 15min to mix evenly, add the remaining water for injection to make up to 1000L, stir evenly to obtain the drug solution, and measure its pH to be 3.34. (4) After the drug solution is prepared, vacuum defoaming is performed with a negative pressure of -0.092MPa until there are basically no bubbles rising in the observation microscope. Secondary sterilization filtration is performed using polyethersulfone filter membranes with pore sizes of 1.0μm and 0.22μm. 150mL / vial is then filled to obtain the oral solution.
[0033] Comparative Example 1 ① A method for producing vancomycin hydrochloride oral solution, comprising the following steps: (1) Add 360 mL of water for injection to a 1000 mL mixing tank, and add 1.92 g of citric acid, 0.84 g of sodium dihydrogen phosphate, 0.021 g of disodium ethylenediaminetetraacetic acid (EDTA) and 0.72 g of potassium sorbate while stirring. Stir until completely dissolved. (2) Add 0.039 g of polydimethylsiloxane to the mixed solution obtained in step (1), stir and disperse evenly, and adjust its pH to 2.84 with citric acid aqueous solution and / or sodium dihydrogen phosphate aqueous solution to prepare a blank matrix solution; (3) Under light-protected conditions, add 180 mL of water for injection to another mixing tank, add 15.23 g of vancomycin hydrochloride, stir until completely dissolved, then mix with the blank matrix solution in step (2), stir for 15 min to mix evenly, add the remaining water for injection to make up to 1000 mL, stir evenly to obtain the drug solution, and measure its pH as 3.02. (4) After the medicine solution is prepared, the laboratory vacuum pump is used to defoam the solution under negative pressure until there are no bubbles in the bottle. The medicine solution is filtered with a 0.22μm polypropylene filter membrane and filled into 150mL / bottle to obtain the oral solution.
[0034] ② A method for producing vancomycin hydrochloride oral solution, comprising the following steps: (1) Add 360 mL of water for injection to a 1000 mL mixing tank, and add 1.92 g of citric acid, 0.84 g of sodium dihydrogen phosphate, 0.021 g of disodium ethylenediaminetetraacetic acid (EDTA) and 0.72 g of potassium sorbate while stirring. Stir until completely dissolved. (2) Add 24.90g of hydroxypropyl-β-cyclodextrin to the mixed solution obtained in step (1), stir continuously for 0.5h until it is completely swollen and clear, then add 0.039g of polydimethylsiloxane, stir and disperse evenly, and adjust its pH to 2.88 with citric acid aqueous solution and / or sodium dihydrogen phosphate aqueous solution to prepare a blank matrix solution; (3) Under light-protected conditions, add 180 mL of water for injection to another mixing tank, add 15.23 g of vancomycin hydrochloride, stir until completely dissolved, then mix with the blank matrix solution in step (2), stir for 15 min to mix evenly, add the remaining water for injection to make up to 1000 mL, stir evenly to obtain the drug solution, and measure its pH to be 3.06. (4) After the medicine solution is prepared, the laboratory vacuum pump is used to defoam the solution under negative pressure until there are no bubbles in the bottle. The medicine solution is filtered with a 0.22μm polypropylene filter membrane and filled into 150mL / bottle to obtain the oral solution.
[0035] ③ A method for producing vancomycin hydrochloride oral solution, comprising the following steps: (1) Add 360 mL of water for injection to a 1000 mL mixing tank, and add 1.92 g of citric acid, 0.84 g of sodium dihydrogen phosphate, 0.021 g of disodium ethylenediaminetetraacetic acid (EDTA) and 0.72 g of potassium sorbate while stirring. Stir until completely dissolved. (2) Add 4.43g L-glutamine to the mixed solution obtained in step (1), stir to dissolve, then add 0.039g polydimethylsiloxane, stir to disperse evenly, and adjust its pH to 2.91 with citric acid aqueous solution and / or sodium dihydrogen phosphate aqueous solution to prepare a blank matrix solution; (3) Under light-protected conditions, add 180 mL of water for injection to another mixing tank, add 15.23 g of vancomycin hydrochloride, stir until completely dissolved, then mix with the blank matrix solution in step (2), stir for 15 min to mix evenly, add the remaining water for injection to make up to 1000 mL, stir evenly to obtain the drug solution, and measure its pH to be 3.08. (4) After the medicine solution is prepared, the laboratory vacuum pump is used to defoam the solution under negative pressure until there are no bubbles in the bottle. The medicine solution is filtered with a 0.22μm polypropylene filter membrane and filled into 150mL / bottle to obtain the oral solution.
[0036] Comparative Example 2 A method for large-scale production of vancomycin hydrochloride oral solution includes the following steps: (1) Add 360L of water for injection to a 1000L mixing tank, and add 1.92kg of citric acid, 0.84kg of sodium dihydrogen phosphate and 0.72kg of potassium sorbate while stirring, and stir until completely dissolved; (2) Add 24.90 kg of hydroxypropyl-β-cyclodextrin to the mixed solution obtained in step (1), and stir continuously for 0.5 h until it is completely swollen and clear. First add 4.43 kg of L-glutamine, stir to dissolve, then add 0.039 kg of polydimethylsiloxane, stir to disperse evenly, and adjust its pH to 3.05 with citric acid aqueous solution and / or sodium dihydrogen phosphate aqueous solution to prepare a blank matrix solution; (3) Under light-protected conditions, add 180L of water for injection to another mixing tank, add 15.23kg of vancomycin hydrochloride, stir until completely dissolved, then mix with the blank matrix solution in step (2), stir for 15min to mix evenly, add the remaining water for injection to make up to 1000L, stir evenly to obtain the drug solution, and measure its pH to be 3.22. (4) After the drug solution is prepared, vacuum defoaming is performed with a negative pressure of -0.092MPa until there are basically no bubbles rising in the observation microscope. Secondary sterilization filtration is performed using polypropylene filter membranes with pore sizes of 1.0μm and 0.22μm. 150mL / vial is then filled to obtain the oral solution.
[0037] Comparative Example 3 A method for large-scale production of vancomycin hydrochloride oral solution includes the following steps: (1) Add 360L of water for injection to a 1000L mixing tank, and add 1.92kg of citric acid, 0.84kg of sodium dihydrogen phosphate, 0.021kg of disodium ethylenediaminetetraacetic acid (EDTA) and 0.72kg of potassium sorbate while stirring, and stir until completely dissolved; (2) Add 24.90 kg of hydroxypropyl-β-cyclodextrin to the mixed solution obtained in step (1), and stir continuously for 0.5 h until it is completely swollen and clear. First add 4.43 kg of L-glutamine, stir to dissolve, and adjust its pH to 3.03 using citric acid aqueous solution and / or sodium dihydrogen phosphate aqueous solution to prepare a blank matrix solution. (3) Under light-protected conditions, add 180L of water for injection to another mixing tank, add 15.23kg of vancomycin hydrochloride, stir until completely dissolved, then mix with the blank matrix solution in step (2), stir for 15min to mix evenly, add the remaining water for injection to make up to 1000L, stir evenly to obtain the drug solution, and measure its pH to be 3.18. (4) After the drug solution was prepared, it was defoamed under a negative pressure vacuum of -0.092MPa until there were basically no bubbles rising in the observation microscope. Secondary sterilization filtration was performed using polypropylene filter membranes with pore sizes of 1.0μm and 0.22μm. Filtration difficulties occurred, and the machine was stopped midway through the process using the 0.22μm filter membrane. 150mL / vial was filled to obtain the oral solution. The fill volume difference was found to be about 2% exceeding the ±5% limit, and bubbles could be clearly observed in the filled bottles.
[0038] The oral solutions prepared in the examples, comparative examples, and reference formulation (24014) were subjected to taste evaluation, and the results are shown in Table 1. The reference formulation was manufactured by AZURITY under the trade name Firvanq Kit. The electronic tongue taste detection method (mainstream potentiometric INSENT / Alpha MOS general standard procedure) simulates human taste buds. The electronic tongue consists of a multi-channel taste sensor array, a reference electrode, a signal acquisition unit, and analysis software.
[0039] Table 1. Taste evaluation results of the examples, comparative examples, and reference formulations.
[0040] From Table 1 and Figures 1-2 It can be seen that the oral solutions prepared in Examples 1-3 of this invention, in terms of nine taste dimensions—sourness, bitterness, astringency, bitter aftertaste, astringent aftertaste, umami, richness, saltiness, and sweetness—are basically consistent with the reference preparation. Figure 1In the comparison, the samples in Examples 1-3 largely overlapped with the reference formulation in nine dimensions, exhibiting less bitterness than the reference formulation, with Example 1 showing the best masking effect. However, in Comparative Examples 1 (①-③), neither hydroxypropyl-β-cyclodextrin nor L-glutamine were added, or only one of them was added for masking, resulting in... Figure 2 It can be seen that its taste is much better than the reference preparation and Examples 1-3 in all five dimensions: sourness, bitterness, astringency, bitter aftertaste, and astringency aftertaste. This indicates that its bitterness and astringency are significantly greater than those of the reference preparation and the examples of this application, resulting in a poorer taste.
[0041] The oral solutions prepared in the examples and comparative examples were investigated for their properties, pH value, potency (%), content (%), related substances and influencing factors. Related substances were detected according to the EP Pharmacopoeia method. Impurities F and G were the impurities F and G listed in the EP Pharmacopoeia. The remaining impurities were basically unchanged and were not listed for the time being. The results are shown in Tables 2 and 3.
[0042] Table 2. Results of key quality indicators for the drug solution on day 0 and for influencing factors (60℃ / 30 days) in the examples.
[0043] Table 3. Test results of key quality indicators of the reference preparation and comparative traditional Chinese medicine solution at day 0 and influencing factors (60℃ / 30 days).
[0044] As shown in Table 2, the oral solutions prepared in Examples 1-3 of this invention showed little change in content, potency, and related substances at 0 days and high temperature (60℃ / 30 days). They had few impurities, and the solution was stable and uniform, exhibiting good stability.
[0045] As shown in Table 3, in Comparative Example 2, the sample without disodium ethylenediaminetetraacetic acid (EDTA) showed lower content and potency, and higher levels of related impurities at day 0. At high temperatures (60℃ / 30 days), the color darkened, the pH increased, and both content and potency significantly decreased, with a marked increase in impurities and poor stability. In contrast, the reference formulation (dry suspension), after being prepared into a solution and subjected to sampling, showed changes largely consistent with Comparative Example 2: darker color, higher pH, significantly lower content and potency, marked increase in impurities, and poor stability. This indicates that the reference formulation is not suitable for preparation as an oral solution and should only be prepared immediately before use, while the oral solution developed in this invention can remain stable in solution form for a long period.
[0046] The above embodiments are only used to illustrate the technical solutions of the present invention, and are not intended to limit it. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications may still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions may be made to some of the technical features. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A vancomycin hydrochloride oral solution, characterized in that, Each 1 mL of oral solution contains the following components by weight: 14-55 mg of active ingredient (based on vancomycin), 0.005-0.060 mg of disodium ethylenediaminetetraacetate, 0.08-1.66 mg of potassium sorbate, and 0.004-0.084 mg of polydimethylsiloxane; the active ingredient is added in the form of vancomycin hydrochloride, and β-cyclodextrin and amino acids are also added, wherein the molar ratio of β-cyclodextrin, vancomycin hydrochloride, and amino acids is 1.2-1.8:1:2.5-4.0; the β-cyclodextrin is hydroxypropyl-β-cyclodextrin or methyl-β-cyclodextrin; the amino acid is L-glutamine or L-glycine; The preparation method of the oral solution includes the following steps: (1) Add citric acid, sodium dihydrogen phosphate, disodium ethylenediaminetetraacetate and potassium sorbate to a portion of water for injection and stir until completely dissolved; (2) Add β-cyclodextrin to the mixed solution obtained in step (1), stir continuously until it is completely swollen and clear, then add amino acids, stir to dissolve, then add polydimethylsiloxane, stir to disperse evenly, and adjust its pH to 2.8-3.2 with a pH adjuster to prepare a blank matrix solution; (3) Under light-protected conditions, add vancomycin hydrochloride to a portion of water for injection and stir until completely dissolved. The resulting solution is then mixed with the blank matrix solution in step (2), stirred and dispersed evenly. The remaining water for injection is added to make up to volume, and the solution is stirred evenly to obtain the drug solution. The pH of the solution is measured to be 2.5-3.
5. (4) After the medicine solution is prepared, vacuum negative pressure is used to remove bubbles and defoam. The negative pressure is controlled at -0.090~-0.095MPa. Sterilization filtration is carried out by primary filtration and fine filtration. The solution is then filled to obtain the oral solution.
2. The vancomycin hydrochloride oral solution according to claim 1, characterized in that, Each 1 mL of oral solution contains the following components by weight: disodium ethylenediaminetetraacetate 0.008-0.045 mg, potassium sorbate 0.28-1.26 mg, polydimethylsiloxane 0.014-0.064 mg; wherein the molar ratio of β-cyclodextrin, vancomycin hydrochloride and amino acids is 1.4:1:3.
2.
3. The vancomycin hydrochloride oral solution according to claim 2, characterized in that, Each 1 mL of oral solution contains the following components by weight: disodium ethylenediaminetetraacetate 0.012-0.030 mg, potassium sorbate 0.48-0.96 mg, and polydimethylsiloxane 0.024-0.054 mg.
4. The method for scaling up the production of vancomycin hydrochloride oral solution according to claim 1, characterized in that, Includes the following steps: (1) Add citric acid, sodium dihydrogen phosphate, disodium ethylenediaminetetraacetate and potassium sorbate to a portion of water for injection and stir until completely dissolved; (2) Add β-cyclodextrin to the mixed solution obtained in step (1), stir continuously until it is completely swollen and clear, then add amino acids, stir to dissolve, then add polydimethylsiloxane, stir to disperse evenly, and adjust its pH to 2.8-3.2 with a pH adjuster to prepare a blank matrix solution; (3) Under light-protected conditions, add vancomycin hydrochloride to a portion of water for injection and stir until completely dissolved. The resulting solution is then mixed with the blank matrix solution in step (2), stirred and dispersed evenly. The remaining water for injection is added to make up to volume, and the solution is stirred evenly to obtain the drug solution. The pH of the solution is measured to be 2.5-3.
5. (4) After the medicine solution is prepared, vacuum negative pressure is used to remove bubbles and defoam. The negative pressure is controlled at -0.090~-0.095MPa. Sterilization filtration is carried out by primary filtration and fine filtration. The solution is then filled to obtain the oral solution.
5. The method for scaling up the production of vancomycin hydrochloride oral solution according to claim 4, characterized in that, In step (1), the amount of water for injection added is 55-70% of its total amount.
6. The method for scaling up the production of vancomycin hydrochloride oral solution according to claim 4, characterized in that, In step (3), the amount of water for injection added is 15-35% of its total amount.
7. The method for scaling up the production of vancomycin hydrochloride oral solution according to claim 6, characterized in that, In step (3), the amount of water for injection added is 20-25% of its total amount.
8. The method for scaling up the production of vancomycin hydrochloride oral solution according to claim 4, characterized in that, In step (4), the negative pressure is controlled at -0.092 MPa.
9. The method for scaling up the production of vancomycin hydrochloride oral solution according to claim 4, characterized in that, In step (4), the pore sizes of the primary filter and the fine filter are 1.0 μm and 0.22 μm, respectively, and the filter membrane material is polypropylene or polyethersulfone.
Citation Information
Patent Citations
Aqueous solution formulations of vancomycin
CN107106585A
Stabilized glycopeptide antibiotic formulations
CN109069580A
